Subtype
Malignant Neoplasm of Unknown Primary
CI-CAN-00001150CUPExplore in graph →
4,163 active trials54 approved drugs532 evidence items
- NCIt
- C8566
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001150CUPExplore in graph →
Clinical trials
14,260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,895)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06523049 | Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy | not yet recruiting | Phase 2 | 67 | Hao ZengOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06523582 | Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients | recruiting | — | 750 | Universidad Nacional Autonoma de MexicoOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06138028 | Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer | recruiting | Phase 2 / Phase 3 | 90 | Qingdao Central HospitalOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06518226 | Two-Fraction Ultrahypofractionated Radiotherapy With Focal Boost for Intermediate Risk, Localized Prostate Cancer(TURBO) | recruiting | N/A | 160 | UMC UtrechtOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06518434 | A Pilot Study on the Effect of Cannabis Oil in Untreatable Liver Cancer Patients(CanHep) | recruiting | Phase 2 | 20 | University Medical Center GroningenOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06514118 | Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer | recruiting | — | 70 | Qingdao Central HospitalOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06295926 | Serplulimab Combined With CCRT for LS-SCLC. | recruiting | Phase 2 | 96 | Peking Union Medical College HospitalOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06512467 | Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 22, 2024 | clinicaltrials |
| NCT06508229 | Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC | not yet recruiting | Phase 2 | 65 | Harbin Medical UniversityOTHER | 0 | Jul 18, 2024 | clinicaltrials |
| NCT06354140 | PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY | recruiting | Phase 2 | 45 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT02021604 | Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma | recruiting | Phase 1 | 250 | Cook Children's Health Care SystemOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT05844046 | Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients(MONTBLANC) | recruiting | Phase 2 | 83 | Enrico De ToniOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06498622 | Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab | recruiting | Phase 2 | 45 | Anhui Provincial HospitalOTHER_GOV | 1 | Jul 12, 2024 | clinicaltrials |
| NCT06496815 | Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy | not yet recruiting | Phase 4 | 32 | Tongji HospitalOTHER | 0 | Jul 11, 2024 | clinicaltrials |
| NCT06497322 | Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic Treatment | not yet recruiting | N/A | 60 | University Hospital of CologneOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT06492317 | RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer | not yet recruiting | Phase 2 | 20 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT06491134 | Liposomal Irinotecan With Cisplatin and Concurrent Radiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 1 | 12 | Hebei Medical University Fourth HospitalOTHER | 0 | Jul 8, 2024 | clinicaltrials |
| NCT05635487 | A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients | recruiting | Phase 2 | 65 | Shengjing HospitalOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT06466902 | Evaluation of Intra-operative Photographs for the Assessment of a Proper Lymphadenectomy in Minimally-invasive Gastrectomies for Gastric Cancer (PhotoNodes)(PhotoNodes) | recruiting | — | 326 | Azienda Ospedaliero-Universitaria di ParmaOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT06487702 | A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 70 | Rui-hua Xu, MD, PhDOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT06138769 | Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma | active not recruiting | Phase 2 | 50 | Asan Medical CenterOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06485544 | Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial | recruiting | Phase 2 | 104 | Tang-Du HospitalOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06485739 | Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma | not yet recruiting | Phase 4 | 20 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 0 | Jul 3, 2024 | clinicaltrials |
| NCT04688528 | Dose De-escalation and Sentinel LN Mapping Driven Radiotherapy of Contralateral Neck in Ipsilateral Node Positive HNSCC(SEMIRAHN) | recruiting | N/A | 147 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06462105 | Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer | not yet recruiting | N/A | 60 | Zhou ChengzhiOTHER | 0 | Jun 28, 2024 | clinicaltrials |
| NCT04790305 | Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer | recruiting | Phase 4 | 1,072 | Fudan UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06196697 | AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer | recruiting | Phase 2 | 50 | Harbin Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06478264 | A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma | not yet recruiting | Phase 2 | 40 | Zhangzhou Municipal HospitalOTHER | 0 | Jun 27, 2024 | clinicaltrials |
| NCT06478927 | Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib | recruiting | N/A | 22 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 27, 2024 | clinicaltrials |
| NCT04952272 | Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors | recruiting | Phase 1 | 50 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06475209 | Adebrelimab + Apatinib in SCLC Maintenance Therapy | recruiting | Phase 2 | 60 | Tang-Du HospitalOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03198546 | GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04803318 | Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors | recruiting | Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06472388 | Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors(EVENET) | recruiting | Phase 2 | 100 | AC Camargo Cancer CenterOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06472895 | A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jun 25, 2024 | clinicaltrials |
| NCT06470256 | Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma | recruiting | Phase 1 | 50 | Zhiyong HuangOTHER | 1 | Jun 24, 2024 | clinicaltrials |
| NCT06467786 | Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer | recruiting | Phase 4 | 24 | Tang-Du HospitalOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT06468644 | Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 60 | Fujian Cancer HospitalOTHER_GOV | 0 | Jun 21, 2024 | clinicaltrials |
| NCT06468670 | Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 0 | Jun 21, 2024 | clinicaltrials |
| NCT04340986 | Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma(CHC/CC) | recruiting | — | 1,250 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT06110572 | Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation(TESSERACT) | recruiting | Phase 1 / Phase 2 | 18 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT06463834 | A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 1 | Jun 18, 2024 | clinicaltrials |
| NCT06464068 | AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA(DURVASCC) | recruiting | Phase 2 | 66 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT02293980 | A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) | active not recruiting | Phase 1 | 110 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jun 17, 2024 | clinicaltrials |
| NCT06371482 | Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01) | recruiting | Phase 2 | 58 | Hebei Medical University Fourth HospitalOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT05701241 | Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients(SAUNA) | recruiting | Phase 4 | 270 | University Hospital, AntwerpOTHER | 2 | Jun 14, 2024 | clinicaltrials |
| NCT06448611 | Identification and Characterization of Circulating Tumor Cells Before and After Treatment (Surgery and Radiotherapy) in a Cohort of Patients Treated for Resectable Stage I-III Merkel Cell Carcinoma(MERCCALIBI) | not yet recruiting | — | 25 | University Hospital, MontpellierOTHER | 0 | Jun 13, 2024 | clinicaltrials |
| NCT06454435 | Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer | not yet recruiting | Phase 2 | 158 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 12, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jul 26, 2024source: clinicaltrials